Inspire Medical Systems (NYSE:INSP – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at KeyCorp in a research note issued to investors on Friday,Benzinga ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $231.12, a high ...

KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...

Stifel analysts adjusted their outlook on Inspire Medical Systems (NYSE:INSP), reducing the price target to $190 from the previous $200 while maintaining a Hold rating on the stock. The revision ...

Medicare covers sleep tests for certain conditions such as sleep apnea, narcolepsy, or parasomnia, but limitations may apply.

Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

The pathophysiology of residual sleepiness in treated obstructive sleep apnoea (OSA) remains poorly understood. Animal models ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

Inspire is dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea. Disclaimer: This is an AI-generated summary of a press ...

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s ...